AI assistant
Vicore Pharma Holding AGM Information 2023
3211_rns_2023-07-05_be10fe00-2d03-414d-a24b-c9f9df6a459b.pdf
AGM Information
Open in viewerOpens in your device viewer
Bulletin from the extraordinary general meeting of Vicore Pharma Holding AB (publ)
The extraordinary general meeting (the "EGM") of Vicore Pharma Holding AB (publ) on 5 July 2023 was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting).
The EGM resolved to approve the board of directors' resolution from 9 June 2023 to issue no more than 20,675,000 new shares at a subscription price of the shares' quota value. The right to subscribe for the new shares shall, with deviation from the shareholders' pre-emption rights, be granted Carnegie Investment Bank AB (publ) solely, which acts as settlement bank in the new issue on behalf of a number of institutional investors. The reasons for the deviation from the shareholders' preemption rights are that the company shall, in a timely manner, be able to secure the capital need for the company's operations, as well as to broaden the ownership structure of the company with Swedish and international institutional investors.
Stockholm, 5 July 2023 Vicore Pharma Holding AB (publ)
For further information, please contact:
Carl-Johan Dalsgaard, CEO Phone: +46 70 975 98 63 E-mail: [email protected]
Hans Jeppsson, CFO Phone: +46 70 553 14 65 E-mail: [email protected]
The information was submitted for publication, through the agency of the contact persons set out above, on 5 July 2023 at 11:15 CEST.
About Vicore Pharma Holding AB (publ)
Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in a phase 2a study of IPF. C21 is protected by US and European orphan drug designation. A variety of patents have been filed to provide further protection for C21, out to 2040 and onwards. Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. Using its unique expertise in the ATRAG biology Vicore is further fueling its pipeline with several new small molecule drug assets, with long patent life and for a
variety of indications, some of which could be partnered while others may be taken to the market by Vicore.
The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.
Attachments
Bulletin from the extraordinary general meeting of Vicore Pharma Holding AB (publ)